Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

eXoZymes, Inc.

Company price
3.3 USD -0.08 ( 2.37%)
Last update at 2026-11-20T14:31:00Z
VOLUME
1406
Market Cap
61.02M

Momentum Score

…

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.30
Low
3.31
High
52 Week Price Range
4.35
Low
18.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on eXoZymes, Inc. is limited; the company is a Nasdaq-listed life sciences firm that appears focused on enzyme-based technologies and related therapeutics. Long-term growth may be driven by clinical or product development milestones, strategic partnerships, and successful commercialization if pipelines advance. Investors may find exposure to enzyme-focused biotech innovation coupled with potential upside from milestone achievements.
Material risks include development and regulatory uncertainty, likely limited revenue and the need for additional financing, and strong competition in the biotech sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.38
Dividend Yield
-
Revenue TTM
-0.00M
Revenue Per Share
-
Gross Profit TTM
-0.00M
Debt / Equity
0.37
ROE
-187.16%
Net Debt
-1.80M
ROCE
-220.60%
Diluted EPS TTM
-1.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -9.26M -5.86M -2.00M -1.33M -1.21M
Net income -9.16M -5.86M -2.04M -1.40M -1.21M
Selling general administrative 5.91M 4.06M 1.34M 0.98M 0.84M
Gross profit - -0.27M - -0.15M -0.06M
Reconciled depreciation 0.29M 0.27M 0.20M 0.15M 0.06M
Ebit -9.72M -5.86M -1.80M -1.33M -1.21M
Ebitda -9.43M -5.59M -1.60M -1.18M -1.15M
Depreciation and amortization 0.29M 0.27M 0.20M 0.15M 0.06M
Operating income -9.72M -5.93M -1.80M -1.33M -1.29M
Other operating expenses 9.72M 5.93M 1.80M 1.33M 1.29M
Tax provision -0.11M 0.00M 0.04M 0.06M 0.00M
Interest income - - 0.00M 0.00M 0.00M
Net interest income 0.36M 0.08M 0.00M 0.00M 0.00M
Income tax expense -0.11M - 0.04M 0.06M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 9.72M 5.66M 1.80M 1.18M 1.23M
Cost of revenue - 0.27M - 0.15M 0.06M
Total other income expense net 0.45M 0.07M -0.20M 0.00M 0.08M
Net income from continuing ops -9.16M -5.86M -2.04M -1.40M -1.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.97M 13.03M 3.56M 2.69M 2.35M
Other current assets 0.38M 0.36M 0.26M 0.10M 0.03M
Total liab 2.57M 2.61M 3.94M 1.31M 1.15M
Total stockholder equity 3.40M 10.42M -0.38M 1.37M 1.20M
Other current liab 0.01M 0.18M 1.45M 0.04M -0.13M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -21.10M -11.95M -6.08M -4.05M -2.65M
Cash 3.04M 9.72M 0.07M 0.56M 0.55M
Total current liabilities 1.57M 1.33M 2.42M 0.63M 0.40M
Net debt -1.80M -8.33M 1.55M 0.05M 0.17M
Short term debt 0.33M 0.23M 0.22M 0.15M 0.13M
Short long term debt total 1.24M 1.39M 1.61M 0.61M 0.72M
Other stockholder equity 24.50M 22.37M 5.70M 5.42M 3.85M
Total current assets 3.94M 10.82M 1.21M 1.47M 1.05M
Net receivables 0.52M 0.74M 0.88M 0.81M 0.47M
Accounts payable 1.24M 0.92M 0.70M 0.39M 0.27M
Non currrent assets other -0.18M - - - -
Non current assets total 2.03M 2.21M 2.34M 1.22M 1.30M
Capital lease obligations 1.24M 1.39M 1.61M 0.61M 0.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.36M -0.31M -0.09M -0.31M
Total cashflows from investing activities -0.15M -0.36M -0.31M -0.09M -0.31M
Net borrowings -0.03M 0.00M - - -
Total cash from financing activities -0.03M 18.52M 1.00M 1.36M 2.31M
Net income -9.16M -5.86M -2.04M -1.40M -1.21M
Change in cash -6.68M 9.65M -0.49M 0.01M 0.41M
Begin period cash flow 9.72M 0.07M 0.56M 0.55M 0.13M
End period cash flow 3.04M 9.72M 0.07M 0.56M 0.55M
Total cash from operating activities -6.50M -8.51M -1.18M -1.26M -1.59M
Issuance of capital stock 0.00M 14.53M 0.00M 1.36M 2.31M
Depreciation -0.05M 0.27M 0.20M 0.15M 0.06M
Other cashflows from investing activities 0.02M 0.04M -0.02M 0.10M 0.11M
Change to account receivables 0.11M 0.15M -0.07M -0.34M -0.32M
Other cashflows from financing activities -0.03M 0.01M 1.00M - -
Capital expenditures 0.17M 0.40M 0.29M 0.19M 0.42M
Change in working capital 0.38M -4.02M 0.22M -0.19M -0.54M
Stock based compensation 1.99M 1.13M 0.28M 0.22M 0.20M
Other non cash items 0.34M -0.02M 0.16M -0.04M -0.10M
Free cash flow -6.67M -8.90M -1.47M -1.44M -2.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
EXOZ
eXoZymes, Inc.
-0.08
2.37%
3.30 - - - 15.95
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
9.17
0.99%
932.51 29.07 20.12 7.57 3.82
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12

Profile*

eXoZymes, Inc.

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

750 Royal Oaks Drive, Monrovia, CA, United States, 91016

626 415 1488

32

Name Title Year Born
Mr. Michael Heltzen President & CEO 1981
Dr. Tyler Korman Ph.D. Co-Founder & Chief Scientific Officer 1979
Dr. Paul Opgenorth Ph.D. Co-Founder & Vice President of Development 1983
Mr. James U. Bowie Ph.D. Founder & Independent Director 1962
Mr. Fouad Nawaz Vice President of Finance 1986
Mr. Damien A. Perriman Chief Commercial Officer 1977
Mr. Lasse H. Gorlitz Vice President of Communications NA
Mr. Michael Burns Executive Vice President of Energy Transition NA
Ms. Amy Lunzer Chief of Staff NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…